TRIM29 Reverses Oxaliplatin Resistance of P53 Mutant Colon Cancer Cell

BACKGROUND: Oxaliplatin is the first-choice chemotherapy method for patients with advanced colon cancer. However, its resistance leads to treatment failure for many patients. In our experiments, we aim to elucidate the associations among TRIM29 protein, mutant P53, and the resistance of colon cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Lei, Guoqiong, Liu, Sushun, Yang, Xin, He, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007381/
https://www.ncbi.nlm.nih.gov/pubmed/33824865
http://dx.doi.org/10.1155/2021/8870907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007381/
https://www.ncbi.nlm.nih.gov/pubmed/33824865
http://dx.doi.org/10.1155/2021/8870907

Ejemplares similares